Clik here to view.
The Dragonfly Foundation Receives SBB Research Group Foundation Grant
CHICAGO The Chicago Chapter of the Dragonfly Foundation received a $5,000 grant from the SBB Research Group Foundation, which awards monthly grants to support impactful organizations during the...
View ArticleClik here to view.
Biocytogen Announces Collaboration with FineImmune to Develop TCR-Mimic...
BEIJING & GUANGZHOU, China Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) announced a strategic collaboration with Guangzhou FineImmune Biotechnology Co., LTD....
View ArticleClik here to view.
ImmunoScape To Present at the 7th Annual CAR-TCR Summit
SAN DIEGO & SINGAPORE ImmunoScape, a pre-clinical biotechnology company focused on the discovery and development of next-generation TCR-T-cell therapeutics, today announced that Dan MacLeod,...
View ArticleClik here to view.
オリンパスがVISERA ELITE III外科可視化プラットフォームを発売
東京 （ビジネスワイヤ） — オリンパス株式会社（取締役 代表執行役 社長兼CEO：竹内康雄）は本日、複数の診療科目にわたる医療従事者の内視鏡手術ニーズに応える最新の外科可視化プラットフォーム「VISERA ELITE III」の発売を発表しました。VISERA ELITE...
View ArticleClik here to view.
奥林巴斯推出VISERA ELITE III手术可视化平台
东京 (美国商业资讯)–奥林巴斯株式会社（Olympus Corporation，简称“奥林巴斯”，取缔役、代表执行役、社长兼首席执行官：竹内康雄）今天宣布推出其最新的手术可视化平台VISERA ELITE III，以满足多科室医疗保健专业人员(HCP)对内窥镜手术的需求。VISERA ELITE...
View ArticleClik here to view.
Clik here to view.
Clik here to view.
阿联酋Burjeel Medical City成功实施首例肾脏移植手术
阿联酋阿布扎比 (美国商业资讯)–阿联酋阿布扎比的私立医院Burjeel Medical City (BMC)已开始实施肾脏移植手术，为本地和国际患者提供肾脏移植选择。BMC是Burjeel Holdings旗下一个卓越的四级医疗中心，为来自哈萨克斯坦的一名患者成功实施了首例肾脏移植手术。 本新闻稿包含多媒体。此处查看新闻稿全文：...
View ArticleClik here to view.
FDA Approves RECOVER IV Randomized Controlled Trial with Exception from...
DANVERS, Mass. Abiomed (Nasdaq: ABMD) announces two approvals from the U.S. Food and Drug Administration (FDA) related to clinical research of Impella heart pumps in acute myocardial infarction...
View ArticleClik here to view.
2023年度SPIE创业挑战赛现已开放申请
华盛顿州贝灵汉 (美国商业资讯)–2023年度SPIE创业挑战赛现已开始接受申请。该年度创业募投比赛由SPIE（国际光学和光子学学会）举办，是SPIE西部光电展(Photonics West)的一部分。2023年西部光电展将于1月28日至2月2日在旧金山Moscone中心举行，SPIE创业挑战赛决赛将于1月31日举行。 本新闻稿包含多媒体。此处查看新闻稿全文：...
View ArticleClik here to view.
Unloading with Impella for 30 Minutes Before PCI Associated with Reduced...
BOSTON Results of a new per-protocol analysis of the ST-segment Elevation Myocardial Infarction Door-To-Unload (STEMI DTU) pilot trial data show significantly reduced infarct size in patients who...
View ArticleClik here to view.
UAEのバージール・メディカル・シティが初の腎臓移植を成功裏に実施
アラブ首長国連邦アブダビ （ビジネスワイヤ） — アラブ首長国連邦アブダビの民間病院において国内外の患者に腎臓移植の選択肢を提供するバージール・メディカル・シティ（BMC）は、腎臓移植の実施を開始しました。バージール・ホールディングス傘下の4次卓越医療センターであるBMCでは、カザフスタン出身の患者に初めて腎臓移植が成功裏に行われました。...
View ArticleClik here to view.
Large, Multi-Center, Multi-Society Study of Impella-supported Patients Finds...
BOSTON Results of a three-year, investigator-led study of all Impella-supported patients treated at 109 hospitals in Japan (n=1,344) show 30-day survival rates of 81% for AMI cardiogenic shock...
View ArticleClik here to view.
NTT Research Names Takashi Goto Head of the Technology Promotion Team
SUNNYVALE, Calif. NTT Research, Inc., a division of NTT (TYO:9432), today announced that it has named Takashi Goto as head of its Technology Promotion Team, a group set up to help productize...
View ArticleClik here to view.
LEO Pharma获得人用医药产品委员会关于Adtralza® (tralokinumab)治疗青少年中度至重度特应性皮炎的积极意见
丹麦巴勒鲁普 (美国商业资讯)–全球领先的皮肤病医疗机构LEO Pharma A/S今天宣布，欧洲药品管理局(EMA)人用医药产品委员会(CHMP)已采纳积极意见，建议扩大Adtralza® (tralokinumab)在欧盟的批准使用范围，将12至17岁的中重度特应性皮炎的青少年纳入系统治疗的对象。青少年患者的推荐初始剂量为600 mg，然后每隔一周使用300 mg，与成年患者的剂量相同。...
View ArticleClik here to view.
Seoul Relax Week Meditation Conference 2022 to Be Held with the Theme of...
SEOUL, South Korea The mental health care festival to comfort tired citizens in the era of a continuous pandemic will begin in August. The Seoul Relax Week Meditation Conference 2022, which...
View ArticleClik here to view.
Clik here to view.
オンライン資格確認等システムと連携するPHC株式会社のAll in One方式・医事コンピュータ用ソフトウェアが累計導入数15,000件を突破
東京 （ビジネスワイヤ） — PHC株式会社メディコム事業部（以下、「メディコム」）は、オンライン資格確認等システムと連携する同社の医療機関・保険薬局向け医事コンピュータ用ソフトウェア(*1)の累計導入数が、2022年9月6日をもって15,000件を突破しましたので、お知らせいたします。...
View ArticleClik here to view.
Multi-Center, Multi-Society Study of Impella-supported Patients with...
BOSTON Abiomed (ABMD) announces the result of a three-year, investigator-led study of all Impella-supported patients treated at 109 hospitals in Japan shows a 30-day survival rate of 77% for...
View ArticleClik here to view.
Blood Cancer Discovery Publication Further Validates Exscientia’s AI...
VIENNA & OXFORD, England Exscientia (Nasdaq: EXAI), ETH Zurich, the Medical University of Vienna, and the Center for Molecular Medicine (CeMM) today announced a new publication in Blood Cancer...
View Article